NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease

► NP03, a novel formulation, allows delivery of significantly lower yet pharmacologically active amounts of lithium. ► NP03 ameliorates motor dysfunction and neuropathology in YAC128 HD mice. ► NP03 corrects multiple HD-related molecular deficits in YAC128 HD mice. ► NP03 is safe with no toxicity associated with long-term use in YAC128 HD mice. ► NP03 is neuroprotective in the YAC128 HD mice and a promising approach to treatment of HD.